Phosphodiesterase 4 subtype B (PDE4B)

Phosphodiesterase 4 subtype B (PDE4B) is an intracellular enzyme belonging to the phosphodiesterase superfamily responsible for hydrolyzing cyclic adenosine monophosphate (cAMP) into AMP within cells. It plays a critical role in regulating cellular responses by modulating levels of this key second messenger molecule. Among the four main subtypes within the phosphodiesterase 4 family—PDE4A-D—PDE4B is highly expressed in immune cells such as neutrophils and macrophages where it regulates inflammatory processes by controlling cytokine release and leukocyte activation.[1] Its dysregulation has been implicated in various pathological states including chronic inflammation, fibrotic lung disease, cardiovascular injury following ischemia-reperfusion events,[2] certain cancers,[1] neuropsychiatric disorders,[7] and autoimmune conditions.[6] Pharmacological inhibition increases cellular cAMP concentrations leading to broad anti-inflammatory effects; thus it represents an attractive drug target especially when selectively inhibited over other closely related isoforms due to improved safety profiles.[2][3][6]

Other names

PDE4BPhosphodiesterase IV BcAMP-specific phosphodiesterase 4B

Drugs targeting PDE4B act primarily by inhibiting its enzymatic activity. This leads to increased intracellular cAMP levels which results in downstream anti-inflammatory effects through modulation of cytokine production and immune cell function. The mechanism includes activation of protein kinase A (PKA) pathways that suppress pro-inflammatory gene expression while enhancing anti-inflammatory mediators[3].